Atlas Trials

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

Clinical trial NCT06454578 · RECRUITING

Trial details

NCT number
NCT06454578
Sponsor
Qilu Hospital of Shandong University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Hepatocellular
Start date
2024-07-24
Primary completion
2026-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.